Roche Diagnostics

Roche Elecsys sFlt-1/PlGF ratio for preeclampsia receives FDA 510(k) clearance, offering a fast and reliable way to predict the risk of developing severe preeclampsia

Women's Health

Roche's Elecsys sFlt-1/PlGF ratio for predicting preeclampsia risk receives FDA 510(k) clearance

Identifying patients at high risk of developing severe preeclampsia can lead to better prediction, earlier interventions and reduced adverse outcomes.

Learn More

Latest news

Pathology Lab

Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU

The first and only FDA-approved companion diagnostic for assessing HER2-low status since 2022 is now also approved to aid in the assessment of HER2-ultralow status for patients with MBC.

Learn more

Cardiovascular

Roche receives FDA 510(k) clearance for the first blood test in the U.S. measuring Lp(a) in molar units

The Roche Diagnostics Tina-quant® Lipoprotein (a) Gen.2 Molarity assay is an in-vitro test measuring lipoprotein (a) in a person’s bloodstream (serum and plasma), and will be broadly available on Roche's chemistry systems in the U.S.

Learn more

Point of Care

Roche receives FDA clearance with CLIA waiver for cobas® liat molecular tests to aid in diagnosing sexually transmitted infections at the point of care

FDA CLIA-waived tests broaden access to accurate, easy-to-use diagnostics for all patients in decentralized settings like urgent care centers, retail clinics, and community health venues.

Learn more